老虎證券
Invest
Pricing
Rewards
Support
About
Quotes
TigerAI
登入
立即註冊
Toggle
美股
詳情
本頁面由Tiger Trade Technology Pte. Ltd.提供服務
ASTRAZENECA PLC ADRhedged
53.28
0.0000
成交量:
- -
成交額:
- -
市值:
159.83萬
市盈率:
- -
高:
53.28
開:
53.28
低:
53.28
收:
53.28
52周最高:
56.90
52周最低:
44.36
股本:
3.00萬
流通股本:
1.00萬
量比:
- -
換手率:
- -
股息:
0.58
股息率:
1.08%
淨資產收益率:
--
總資產收益率:
--
市淨率:
--
市盈率(LYR):
- -
資料載入中...
總覽
公司
新聞資訊
公告
概念
沒有相關數據
資金流向
資金流入:
資金流出:
實時
日
周
月
季度
年
新聞資訊
DESTINY-Lung04 III期臨床研究顯示,優赫得®一線治療HER2突變晚期非小細胞肺癌患者的中位無進展生存期達14.3個月
美通社
·
09/14
阿斯利康的乳腺癌藥物晚期臨床試驗失敗
路透中文
·
09/12
阿斯利康股價盤後跌超2%,因其三期臨床試驗結果令人失望。
智通财经
·
09/12
投洽會「金鑰匙」再啓:雙向投資動能強勁,未來產業站上C位
同花顺
·
09/09
{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"老虎國際,美股交易,港股交易,交易美股,股票信息,股價,美股行情,美股打新,港股打新,IPO打新,購買美股,全球投資","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/hant/stock/AZNH"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"AZNH","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AZNH\",,,,,undefined,":{"symbol":"AZNH","market":"US","secType":"STK","nameCN":"ASTRAZENECA PLC ADRhedged","latestPrice":53.2774,"timestamp":1789502400000,"preClose":53.2774,"halted":3,"volume":0,"delay":0,"changeRate":0,"floatShares":10000,"shares":30000,"eps":0,"marketStatus":"停牌","change":0,"latestTime":"09-15 16:00:00 EDT","open":53.2774,"high":53.2774,"low":53.2774,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1789545600000},"marketStatusCode":5,"adr":0,"exchange":"NYSE","adjPreClose":53.2774,"dividendRate":0.010836,"bidAskSpread":0,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AZNH\",,,,,undefined,":{"symbol":"AZNH","floatShares":10000,"roa":"--","roe":"--","lyrEps":0,"shares":30000,"dividePrice":0.57729,"high":53.2774,"amplitude":0,"preClose":53.2774,"low":53.2774,"week52Low":44.36,"pbRate":"--","week52High":56.8955,"institutionHeld":0,"latestPrice":53.2774,"eps":0,"divideRate":0.010836,"volume":0,"delay":0,"ttmEps":0,"open":53.2774,"prevYearClose":54.226,"prevWeekClose":53.2774,"prevMonthClose":53.2774,"prevQuarterClose":53.2774,"fiveDayClose":53.2774,"twentyDayClose":53.2774,"sixtyDayClose":53.2774},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/AZNH\",params:#limit:5,,,undefined,":[{"date":"2025-12-16","symbol":"AZNH","amount":0.57729,"announcedDate":"2025-12-15","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-16","defaultRemindTime":1765895400000,"name":"ASTRAZENECA PLC ADRhedged","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-24","payableDate":"2025-12-16","currency":"USD","dateTimestamp":1765861200000,"payDate":"2025-12-24"},{"date":"2024-12-16","symbol":"AZNH","amount":2.71402,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-16","defaultRemindTime":1734359400000,"name":"ASTRAZENECA PLC ADRhedged","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-23","payableDate":"2024-12-16","currency":"USD","dateTimestamp":1734325200000,"payDate":"2024-12-23"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"AZNH\",market:\"US\",,,undefined,":[{"executeDate":"2024-12-16","recordDate":"2024-12-16","paymentDate":"2024-12-23","value":2.71402,"currency":"USD"},{"executeDate":"2025-12-16","recordDate":"2025-12-16","paymentDate":"2025-12-24","value":0.57729,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"AZNH\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"AZNH\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2667645276","title":"DESTINY-Lung04 III期臨床研究顯示,優赫得®一線治療HER2突變晚期非小細胞肺癌患者的中位無進展生存期達14.3個月","url":"https://stock-news.laohu8.com/highlight/detail?id=2667645276","media":"美通社","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667645276?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 19:16","pubTimestamp":1789384560,"startTime":"0","endTime":"0","summary":"德曲妥珠单抗组的中位PFS为14.3个月,而帕博利珠单抗联合化疗组为8.3个月。\" 阿斯利康全球执行副总裁、肿瘤研发负责人Susan Galbraith表示:\"DESTINY-Lung04是首项在HER2突变晚期NSCLC患者中,证实PFS优于全球一线标准治疗的III期临床研究。在DESTINY-Lung04临床研究中,德曲妥珠单抗的安全性特征与其已知安全谱总体一致,未发现新的安全性问题。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"prnasia","url":"http://wwwold.prnasia.com/story/archive/5046853_ZH46853_1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/5046853_ZH46853_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["IE00B19Z4B17.USD","LU0128525929.USD","DCO","LU0432979614.USD","LU2237443465.HKD","LU0566484027.USD","BK4231","IE00B66KJ199.SGD","LU2237443978.SGD","LU2237443895.HKD","ADC","NETL","BK4007","BK4187","CR","ORR","LU2456880835.USD","FXN","PFS","LU2089984988.USD","PXI","LU2236285917.USD","LU2462157665.USD","LU1829250122.USD","LU0708994859.HKD","LU1267930573.SGD","LU2237443622.USD","ROKT","BK4585","AZNH","BK4568","LU0289739699.SGD","BK4213","LU0058720904.USD","LU0320765992.SGD","LU1559883803.SGD","LU0109394709.USD","LU2417539215.USD","LU0310800379.SGD","BK4588","IE0031619046.USD","IE00B7SZL793.SGD","PR","BK4161","AZN","LU2237443549.SGD","IE00B3T34201.USD","BK4195","BK4211"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666574841","title":"阿斯利康的乳腺癌藥物晚期臨床試驗失敗","url":"https://stock-news.laohu8.com/highlight/detail?id=2666574841","media":"路透中文","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666574841?lang=zh_tw&edition=fundamental","pubTime":"2026-09-12 04:29","pubTimestamp":1789158581,"startTime":"0","endTime":"0","summary":"阿斯利康的乳腺癌药物晚期临床试验失败路透9月11日-阿斯利康(AstraZeneca)AZN.L周五表示,其一款乳腺癌药物在晚期临床试验中未能达到改善无进展生存期的主要目标。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260911:nL4T4531G8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2237443895.HKD","AZN","LU2456880835.USD","LU0889565916.HKD","LU0109394709.USD","BK4585","LU0058720904.USD","LU0320765992.SGD","LU1829250122.USD","LU2462157665.USD","LU2468319806.SGD","LU0310800379.SGD","LU2237443978.SGD","LU2237443465.HKD","LU0029864427.USD","BK4568","LU0289739699.SGD","BK4588","AZNH","LU0708994859.HKD","LU2237443382.USD","LU2417539215.USD","LU0432979614.USD","LU2237443549.SGD","BK4007","LU2236285917.USD","LU0128525929.USD","LU2237443622.USD","IE00B3T34201.USD","LU1267930573.SGD","LU2089984988.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666571008","title":"阿斯利康股價盤後跌超2%,因其三期臨床試驗結果令人失望。","url":"https://stock-news.laohu8.com/highlight/detail?id=2666571008","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666571008?lang=zh_tw&edition=fundamental","pubTime":"2026-09-12 04:23","pubTimestamp":1789158183,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["FBT","HELX","IDNA","RXL","LU2272731600.USD","AZNH","BME","IEHS","BK4585","LU2473716301.USD","IEIH","PPH","LU2272731782.SGD","XBIX","LU2322448791.USD","SYNB","LU2322448957.HKD","LU1992135472.HKD","PJP","MRNY","LU2272731865.HKD","MEDI","IBRN","RSPH","PBE","TMED","GNOM","PBPH","BBP","IBB","BBH","CANC","BK4588","BIB","XPH","BIOY","FTXH","MRNX","IE00B5TLWC47.USD","SBIO","LFSC","PSCH","LU1992135399.USD","WDNA","IYH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666533439","title":"投洽會「金鑰匙」再啓:雙向投資動能強勁,未來產業站上C位","url":"https://stock-news.laohu8.com/highlight/detail?id=2666533439","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666533439?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 20:38","pubTimestamp":1788957480,"startTime":"0","endTime":"0","summary":"9月8日至11日,第二十六届中国国际投资贸易洽谈会(以下简称“投洽会”)在厦门国际博览中心举行。本届大会以“扩大双向投资共促全球发展”为永久主题,围绕“投资中国”“中国投资”“国际投 ...","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20260909/c679754294.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20260909/c679754294.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["LU2237443382.USD","LU0289739699.SGD","AZN","LU2236285917.USD","BK4588","LU2456880835.USD","LU2417539215.USD","AZNH","LU0029864427.USD","LU0058720904.USD","LU2237443622.USD","LU0310800379.SGD","LU1829250122.USD","LU2237443978.SGD","LU2468319806.SGD","LU0708994859.HKD","BK4007","LU0128525929.USD","LU0432979614.USD","LU0320765992.SGD","LU2237443895.HKD","BK4585","IE00B3T34201.USD","LU0889565916.HKD","LU2462157665.USD","LU2237443549.SGD","LU2089984988.USD","BK4568","LU2237443465.HKD","LU1267930573.SGD","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":41,"pageCount":1,"totalSize":163,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/AZNH\",params:#limit:6,delay:false,,,undefined,":[]}}